Bli medlem
Bli medlem

Du är här

2015-12-18

Oncology Venture: Oncology Venture has submitted the APO010 screening protocol

Hoersholm, Denmark; December 18th, 2015 - Oncology Venture Sweden AB
(OV:ST) announces that the screening protocol for APO010 in Multiple
Myeloma (MM) has been submitted to the Ethics Committee. APO010 is a
first in class FASLigand anticancer product in the immuno oncology
field. OV will screen approximately 150 patients and identify 15
patients with the highest likelihood of benefit in the focused phase
2 multi center study. The Drug Response Predictor (DRP™) uses genomic
information from the individual cancer patient's tumor biopsy. This
information is matched with the APO010 DRP™ based on scientific
analysis on cell lines and more than 3000 cancer patients.

"I look very much forward to initiate the screening of Multiple
Myeloma (MM) patients for eligibility for the phase 2 trial with
APO010. MM is a hard to treat cancer disease in the blood where new
treatments are needed. This new immune oncology product mimics our
immune system and is a first in class product which we believe can
become a new treatment option in the Multiple Myeloma indication, "
Said Adjunct professor Peter Buhl Jensen, M.D., CEO of Oncology
Venture. "The APO010 is a FAS-ligand drug and only works when the
FAS-receptor is there but this is not enough and OV use its DRP to
find the high likelihood responders. OV will therefore screen the
patients and include patients with the highest likelihood of
response. I believe that the combination of a unique drug and a
unique Drug Response Predictor technology gives a very high
likelihood of success." Peter Buhl further commented.

About Multiple Myeloma
Multiple myeloma (MM) is a systemic malignancy in the blood affecting
plasma cells. The introduction of high-dose therapy with autologous
stem cell support and introduction of new therapies like the
proteasome inhibitor bortezomib and IMIDs (thalidomide and
lenalidomide) has improved the outcome. In spite of this eventually
all patients will experience progressive disease and continue into
second and later lines of treatment. OV will approach this important
clinical issue by introducing a novel systemic chemotherapeutic
treatment together with a predictive biomarker test.

About APO010
APO010 employing on immune oncology cell signaling strategy to kill
cancer cells. APO010 is a novel chemotherapeutic agent that mimics
cytotoxic T-lymphocyte signaling. The mechanism of action of APO010
is the specific induction of cell death in Fas-expressing cells
through binding to the Fas receptor and activation of
well-characterised Fas-mediated death-receptor pro-apoptotic pathway.
A phase I study has previously been conducted including 26 patients.
In this study the patients were not selected based on likelihood of
benefit from APO010.

About the Drug Response Predictor (DRP™) screening tool
This method builds on the comparison of sensitive and resistant human
cancer cell lines including genomic information from cell lines
combined with clinical tumor biology and clinical correlates in a
systems biology network.

For further information concerning Oncology Venture please contact:
Peter Buhl Jensen, CEO
Telephone: +45 21 60 89 22
E-mail: pbj@oncologyventure.com

About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development
of anti-cancer drugs via its wholly owned Danish subsidiary Oncology
Venture ApS. Oncology Venture has a license to use Drug Response
Prediction - DRP™ - in order to significantly increase the
probability of success in clinical trials. DRP™ has proven its
ability to provide a statistically significant prediction of clinical
outcomes from drug treatment in cancer patients in 26 of the 32
clinical studies that were examined. The Company uses a model that
alters the odds in comparison with traditional pharmaceutical
development. Instead of treating all patients with a particular type
of cancer, patients are screened first and only those who are most
likely to respond to the treatment will be treated. Via a more
well-defined patient group, the risk and costs are reduced while the
development process becomes more efficient.

-----------------------------------------------------------
http://news.cision.com/oncology-venture/r/oncology-venture-has-submitted...
http://mb.cision.com/Main/12685/9887595/458941.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.